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OBJECTIVES Our purpose was to determine whether patients with persistent atrial fibrillation (AF) and
patients with paroxysmal AF show alterations in potassium channel expression.
BACKGROUND Persistent AF is associated with a sustained shortening of the atrial action potential duration
and atrial refractory period. Underlying molecular changes have not been studied in humans.
We investigated whether a changed gene expression of specific potassium channels is
associated with these changes in patients with persistent AF and in patients with paroxysmal
AF.
METHODS Right atrial appendages were obtained from 8 patients with paroxysmal AF, 10 with
persistent AF and 18 matched controls in sinus rhythm. All controls underwent coronary
artery bypass surgery, whereas most AF patients underwent Cox’s MAZE surgery (atrial
arrhythmia surgery to cure AF) (n 5 12). All patients had normal left ventricular function.
mRNA (ribonucleic acid) levels were measured by semiquantitative polymerase chain reaction
and protein content by Western blotting.
RESULTS mRNA levels of transient outward channel (Kv4.3), acetylcholine-dependent potassium
channel (Kir3.4) and ATP-dependent potassium channel (Kir6.2) were reduced in patients
with persistent AF (235%, 247% and 236%, respectively, p , 0.05), whereas only Kv4.3
mRNA level was reduced in patients with paroxysmal AF (229%, p 5 0.03). No changes
were found for Kv1.5 and HERG mRNA levels in either group. Protein levels of Kv4.3,
Kv1.5 and Kir3.1 were reduced both in patients with persistent AF (239%, 284% and
247%, respectively, p , 0.05) and in those with paroxysmal AF (257%, 264%, and 240%,
respectively, p , 0.05).
CONCLUSIONS Persistent AF is accompanied by reductions in mRNA and protein levels of several potassium
channels. In patients with paroxysmal AF these reductions were observed predominantly at
the protein level and not at the mRNA level, suggesting a post-transcriptional regulation.
(J Am Coll Cardiol 2001;37:926–32) © 2001 by the American College of Cardiology
Atrial fibrillation (AF) is a common cardiac arrhythmia
affecting millions of people worldwide (1). Atrial fibrillation
has the tendency to become more persistent and increasingly
difficult to treat over time. During recent years, experimen-
tal studies showed that shortening of the atrial effective
refractory period was one important factor contributing to
the persistence of AF (2,3). This shortening has been
confirmed in patients suffering from AF and atrial flutter
(4,5). Experimental and human data revealed that AF- or
tachycardia-induced shortening of atrial effective refractory
period and action potential duration were associated with a
reduction of ICaL, ITo1 and INa currents because of reduced
mRNA (ribonucleic acid) expression of these channels (6–9).
Previously we have demonstrated that mRNA and protein
expression of the L-type calcium channel in patients with
persistent AF and more severe underlying heart disease (10)
and in the present patient population (11) were significantly
reduced. No alterations, however, were observed in patients
with either paroxysmal or short-term persistent AF.
Theoretically, action potential duration and atrial effec-
tive refractory period can be shortened by 1) an increase in
K1 channel gene expression and activity, 2) a decrease in
L-type Ca21 channel (L-type Ca21) gene expression and
activity or 3) a combination of both. The present study was
undertaken to evaluate the impact of both persistent AF and
paroxysmal AF on gene expression of potassium channels in
human right atrial appendages. Therefore, the mRNA and
protein expression of Kv4.3 (gene underlying the calcium
independent transient outward current ITo1) (12), HERG
(gene encoding the rapid component of the delayed recti-
From the *Department of Cardiology, †Department of Clinical Pharmacology and
‡Department of Thoracic Surgery, Thoraxcenter University Hospital Groningen,
Groningen, The Netherlands, and the §Department of Cardiology, University of
Amsterdam, The Netherlands and Utrecht, The Netherlands. Dr. Van Gelder was
supported by Grant 94.014 of the Netherlands Heart Foundation, The Hague, The
Netherlands. The study was supported by Grant 96.051 of The Netherlands Heart
Foundation, The Hague, The Netherlands.
Manuscript received October 22, 1999; revised manuscript received September 25,
2000, accepted November 3, 2000.
Journal of the American College of Cardiology Vol. 37, No. 3, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)01195-5
fier) (13), Kv1.5 (gene encoding the ultra-rapid delayed
rectifier, IKur) (14,15), Kir3.1/Kir3.4 (heterotetrameric
complex of these two genes forms the acetylcholine de-
pendent K1 current, IKACh) (16) and Kir6.2 (gene encoding
the inward rectifier K1 current, forming IKATP with the
sulfonylurea receptor) (17) were examined in patients with
persistent AF and in those with paroxysmal AF who were
undergoing cardiac surgery. Patients with lone AF (AF
without underlying disease) or patients with AF scheduled
for coronary artery bypass surgery (CABG) were matched
with patients in sinus rhythm without history of AF and
undergoing CABG.
MATERIALS AND METHODS
Patient selection and atrial tissue collecting. The day
before surgery, one investigator (AET) assessed the clinical
characteristics of the patient. Patients’ history and previous
electrocardiograms were used to establish type and duration
of AF. In addition, medication use and exercise tolerance
(according to the New York Heart Association [NYHA]
classification) were determined. Echocardiography data
were obtained within three months before surgery. Right
atrial appendages were obtained from 10 patients with
persistent AF and from 8 patients with paroxysmal AF. All
patients were euthyroid. The AF patients were matched for
age, gender and degree of heart failure with 18 clinically
stable patients in sinus rhythm undergoing CABG. The
Institutional Review Board approved the study, and all
patients gave written informed consent. Immediately after
excision, the right atrial appendages were snap-frozen in
liquid nitrogen and stored at 285°C.
RNA isolation and cDNA synthesis. Total ribonucleic
acid was isolated and processed as described previously (11).
Briefly, first strand cDNA (deoxyribose nucleic acid) was
synthesized by incubation of 1 mg of total RNA in reverse
transcription 103 buffer, 200 ng of random hexamers with
200 units of Moloney murine leukemia virus reverse tran-
scriptase, 1mM of each dNTP and 1 unit of RNase
inhibitor (Promega, The Netherlands) in 20 ml. Synthesis
reaction was performed for 10 min at 20°C, 20 min at 42°C,
5 min at 99°C and 5 min at 4°C. All the products were
checked for contaminating DNA.
Semiquantitative polymerase chain reaction (PCR) anal-
yses. We have previously described and validated these
methods (11). In short, the cDNA of interest and the
cDNA of the ubiquitously expressed housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were coamplified in a single PCR. Primers (Eurogentec,
Seraing, Belgium) were designed for Kv4.3, HERG, Kv1.5,
Kir3.4, Kir6.2 and the housekeeping gene GAPDH (Table
1).
The PCR products were separated on agarose gel by
electrophoresis and stained with ethidium bromide. The
density of the PCR products was quantified by densitome-
try. Linearity for the PCR was established by making a
correlation between the number of cycles and the density of
gene of interest and GAPDH (data not shown).
Protein preparation and Western blotting. Frozen right
atrial appendages of five patients in sinus rhythm, five
patients with paroxysmal AF and five patients with persis-
tent AF were homogenized in RIPA buffer as previously
Abbreviations and Acronyms
AF 5 atrial fibrillation
CABG 5 coronary artery bypass surgery
DNA 5 deoxyribonucleic acid
GAPDH 5 glyceraldehyde-3-phosphate dehydrogenase
HERG 5 gene encoding rapid component of the
delayed rectifier IKr
Kir3.1 5 gene encoding part of the IKACh, together
with IKir3.4
Kir3.4 5 gene encoding part of the IKACh, together
with IKir3.1
Kir6.2 5 gene encoding part of the IKATP
Kv1.5 5 gene encoding ultra rapid component of the
delayed rectifier IKur
Kv4.3 5 gene underlying calcium independent
transient outward current ITo1
LV 5 left ventricular, left ventricle
NYHA 5 New York Heart Association
PCR 5 polymerase chain reaction
RNA 5 ribonucleic acid
SR 5 sinus rhythm




GAPDH F 59-CCC ATC ACC ATC TTC CAG GAG CG-39, Var. Var.
R 59-GGC AGG GAT GAT GTT CTG GAG AGC C-39.
To1 F 59-CAG CAA GTT CAC AAG CAT CC-39 31 52
Kv4.3 R 59-AGC TGG CAG GTT AGA ATT GG-39.
Kr F 59-GTC AAT GCC AAC GAG GAG GT-39, 27 58
HERG R 59-CTG GTG GAA GCG GAT GAA CT-39
Kur F 59-AAC GAG TCC CAG CGC CAG GT-39 32 64
Kv1.5 R 59-AGG CGG ATG ACT CGG AGG AT-39
KACh F 59-CAC CCT GGT GGA CCT CAA GTG GCG C-39 30 56
Kir3.4 R 59-AGC TCC GGG CTT GGC AGG TCA TGC-39
KATP F 59-CAC GCT GGT GGA CCT CAA GT-39 29 59
Kir6.2 R 59-CAC GAT GAG GCT CAG GAT GG-39
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described (11). Protein concentration was determined ac-
cording to the Bradford method (Sigma, Zwyndrecht, The
Netherlands), with bovine albumin as a standard. Protein
expression was determined by Western blot analysis and
expressed as the ratio to levels of GAPDH. Therefore,
denatured protein (10 mg) was separated by SDS-PAGE,
transferred to nitrocellulose membranes (Stratagene, Am-
sterdam, The Netherlands) and incubated with primary
antibodies against GAPDH (Affinity Reagents, Golden,
Colorado), anti Kir3.1, anti Kv4.3 and anti Kv1.5 (Alomone
Labs, Jerusalem, Israel). Anti-mouse IgG (Santa Cruz
Biotechnology, Heerhugowaard, The Netherlands) was
used as secondary antibody. Signals were detected by the
ECL detection method (Amersham, Roosendaal, The
Netherlands) and quantified by densitometry. The specific-
ity of the band was tested by pre-incubation of the antibody
with the antigen. The band densities were evaluated by
densitometric scanning using a Snap Scan 600 (Agfa,
Ryswyk, The Netherlands). There was a linear relation
between protein amounts on the membrane and immuno-
reactive signals of Kir3.1, Kv4.3, Kv1.5 and GAPDH (data
not shown).
Definitions
Persistent AF. “Persistent AF” is defined as the continuous
presence of AF until the moment of cardiac surgery (i.e., at
least two consecutive electrocardiograms of AF more than
one week apart and without intercurrent sinus rhythm).
Persistent AF has a nonspontaneously converting character.
Previously, this type of AF was classified as “chronic AF”
(18).
Paroxysmal AF. “Paroxysmal AF” typically occurs in epi-
sodes with a duration shorter than 24 h (but longer lasting
paroxysms are not unusual) with intermittent sinus rhythm.
Paroxysmal AF is either spontaneously converting or is
terminated with intravenously administered anti-arrhythmic
drugs. The presence of paroxysmal AF at the moment of
cardiac surgery cannot be controlled (18).
Statistical Analysis
All PCR and SDS-PAGE procedures were performed in
duplicate series, and mean values were used for statistical
analysis. For determination of correlations the Spearman
correlation test was used. One-way analysis of variance was
used for all group comparisons. All p values are two-sided;
a p value ,0.05 was considered statistically significant.
SPSS version 8.0 was used for all statistical evaluations.
RESULTS
Patients. Ten patients with persistent AF and eight pa-
tients with paroxysmal AF were included. These two groups
were compared with two groups of controls in sinus rhythm,
which were matched for gender, age and left ventricular
(LV) function (Table 2). Six of the eight patients with
paroxysmal AF suffered from intractable paroxysmal AF
without any underlying heart disease and were scheduled for
Cox’s MAZE surgery. The median duration of sinus
rhythm before surgery was 1.5 days. The median frequency
of paroxysms was once a day, with a median duration of 3 h.
Three patients with paroxysmal AF were in AF at the
moment of surgery and harvesting of the right atrial
appendage. Control right atrial appendages were obtained
Table 2. Baseline Characteristics of Patients With Paroxysmal AF, Persistent AF and Matched
Control Patients in Sinus Rhythm of Both Groups at the Moment of Surgery
PAF SR (PAF) CAF SR (CAF)
8 8 10 10
M/F (n) 6/2 6/2 6/4 6/4
Age 51 6 7 56 611 63 6 11 65 617
Duration of AF: median, range (months) 18 (8–64)
Duration SR before surgery: median, range (days) 1.5 (0–30)
Underlying heart disease (n)
Coronary artery disease 2* 8 3* 10
Hypertension 1 1 3 2
Lone AF 6* 0 5* 0
Surgical procedure
CABG 2* 8 4* 10
MAZE 6* 0 6* 0
New York Heart Association for exercise tolerance
Class I 7 5 6 5
Class II 1 3 4 5
Medication
Beta-blockers 1* 5 3 6
Calcium antagonist 0 3 3 3
Digitalis 0 1 5 3
ACE inhibitor 0 1 4 2
*p value , 0.05 compared with the control group. Values are presented as mean value 6 SD or number of patients.
ACE 5 angiotensin converting enzyme; AF 5 atrial fibrillation; CABG 5 coronary artery bypass grafting; CAF 5 chronic
persistent atrial fibrillation; M/F 5 male/female; PAF 5 paroxysmal atrial fibrillation; SR (CAF) 5 matched controls in sinus
rhythm of patients with persistent AF; SR (PAF) 5 matched controls in sinus rhythm of patients with paroxysmal AF.
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from clinically stable patients in sinus rhythm who were
scheduled for CABG. Although the AF groups and their
controls in sinus rhythm differed with respect to the
underlying heart disease, all had a normal LV function and
were in functional NYHA class I or II for exercise tolerance.
Also, atrial and LV dimensions were similar among groups
(data not shown).
Alterations in mRNA levels in persistent and paroxysmal
AF. Changes in transcription of the gene of interest were
determined by comparison of gene-of-interest/GAPDH
ratios between patients with persistent or paroxysmal AF
and their matched controls in sinus rhythm. No differences
in GAPDH densities were found between the groups (data
not shown).
Patients with persistent AF showed significant reductions
of mRNA contents for Kv4.3 (235%, p 5 0.02), Kir3.4
(247%, p 5 0.0003) and Kir6.2 (236%, p 5 0.03) (Table
3). Patients with paroxysmal AF showed only reduction of
the Kv4.3 mRNA level (229%, p 5 0.03, Table 3). No
differences in mRNA contents for Kv1.5 and HERG were
found between patients with persistent AF and those with
paroxysmal AF, compared with patients in sinus rhythm
(Table 3). Although the group samples are small, the
mRNA levels of Kv4.3, Kv1.5 and Kir3.4 in both patients
with persistent AF and those with paroxysmal AF seemed
not to be influenced by any drug (data not shown).
Alterations in protein levels in persistent and paroxysmal
AF. From the total patient group there were five patients
with persistent AF, five with paroxysmal AF and five
patients in sinus rhythm with enough right atrial appendage
tissue to isolate proteins. Changes in protein expression
were studied for Kv4.3, Kv1.5 and Kir3.1 in relation to
protein levels of GAPDH. The protein expression of
Kv1.5/GAPDH and Kir3.1/GAPDH was markedly re-
duced in patients with persistent AF compared with pa-
tients in sinus rhythm (284%, p 5 0.001 and 247%, p 5
0.002, respectively) and patients with paroxysmal AF
(264%, p 5 0.005 and 240%, p 5 0.007, respectively, Figs.
1B and C). Similar results were obtained for Kv4.3/
GAPDH protein content (i.e., a reduction both in patients
with persistent AF [239%, p 5 0.04] and in those with
paroxysmal AF [257%, p 5 0.001, Fig. 1A]). A positive
correlation could be demonstrated between mRNA levels
and protein levels of Kv4.3 and Kir3.1, but not of Kv1.5, for
patients with paroxysmal AF, persistent AF and sinus
rhythm (Table 3). Although the group samples are small,
the protein ratio of Kv4.3, Kv1.5 and Kir3.1 seemed not to
be influenced by any drug (data not shown).
Importantly, in patients with paroxysmal AF the mean
protein expression of Kv1.5 appeared to be related to the
duration of sinus rhythm after the last episode of AF.
Patients in AF at the moment of surgery showed the lowest
protein expression, comparable to patients with persistent
AF. Patients in sinus rhythm at the moment of surgery
showed the highest protein expression (Fig. 2).
DISCUSSION
Both experimental (2,3,19,20) and human (4,5,21,22) AF
are accompanied by shortening of the action potential
duration and effective refractory period. This shortening can
be mediated by either an increase in K1 channel gene
products and/or activity, or a decrease in L-type Ca21
channel gene products and/or activity. Previously, we dem-
onstrated a reduced mRNA and protein expression of the
L-type calcium channel in patients with long-standing AF
but not in those with paroxysmal AF (10,11). The present
study shows that in patients with long-standing persistent
AF, the mRNA and protein expression of almost all
investigated potassium channel genes were reduced. In
paroxysmal AF patients, reduction in mRNA levels was
confined to Kv4.3, whereas the investigated protein levels
(Kv4.3, Kv1.5 and Kir3.1) were all decreased. Finally, there
was a significant positive correlation between the duration
of sinus rhythm after the last episode of paroxysmal AF and
content of protein expression of Kv1.5, suggesting a protec-
tive effect of high protein contents or a normalization of
protein content after a longer duration of sinus rhythm.
Differences in mRNA and protein expression. We deter-
mined mRNA and protein levels of genes encoding a
number of potassium channels. Unfortunately, no antibod-
ies against all the potassium channels have yet been gener-
ated. Therefore, we could study only protein expression of
Kv4.3, Kv1.5 and Kir 3.1. Nevertheless, this study reports
profound changes in protein expression in both persistent
and paroxysmal AF. In contrast, reduction of mRNA
contents seems almost an exclusive feature for persistent
AF. The observed reduction in Kv4.3 mRNA expression
Table 3. Comparison of mRNA and Protein Expression for Patients With Persistent and
Paroxysmal AF With their Matched Controls in Sinus Rhythm
mRNA Expression Correlation
mRNA and
ProteinSR1 CAF SR2 PAF
Kv4.3 1.12 6 0.1 0.73 6 0.09* 1.08 6 0.11 0.77 6 0.1† 0.75
Kv1.5 1.35 6 0.12 1.28 6 0.11 1.37 6 0.14 1.56 6 0.14 0.31
HERG 0.43 6 0.04 0.42 6 0.03 0.52 6 0.04 0.62 6 0.03 n.a.
Kir3.4/Kir3.1 1.9 6 0.1 1.03 6 0.1* 1.92 6 0.11 1.59 6 0.13 0.74*
Kir6.2 1.04 6 0.07 0.67 6 0.07* 1.1 6 0.07 0.96 6 0.07 n.a.
*p , 0.005; †p , 0.05.
AF 5 atrial fibrillation; CAF 5 chronic persistent atrial fibrillation; PAF 5 paroxysmal atrial fibrillation; SR 5 sinus rhythm.
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(gene encoding the calcium independent transient outward
current) both in patients with persistent AF and in those
with paroxysmal AF is in accordance with experimental and
human studies (3,8). In dogs subjected to rapid atrial pacing
(400 beats/min), the transient outward current was reduced
by 70% after six weeks (3), with a concomitant reduction of
mRNA and protein expression (6).
In the heart, Kir3.1 and Kir3.4 gene products appear to
be responsible for the acetylcholine-activated K1 current
(16), representing an important atrial inwardly rectifying
current. Activation of this channel (e.g., by vagal stimula-
tion) shortens the action potential duration and refractory
period. The Kir3.4 gene was used for mRNA expression
determination, and a reduction in Kir3.4 mRNA expression
was found in patients with persistent AF. For Western
blotting Kir3.1 was analyzed. A reduction in protein level,
which may occur to protect the cell against further short-
ening of the action potential duration during AF, was
observed both in patients with persistent AF and in those
with paroxysmal AF. The down-regulation observed in our
study is, however, in contrast to findings by others on the
electrophysiological level. In a comparable group of patients
with persistent AF, an increase in inwardly rectifying
currents (IK1 and IKACh) was measured in isolated myocar-
dial cells (23). This apparent inconsistency between protein
level and current density can be explained only by assuming
a change in single-channel properties—such as an increase
of mean open time, an increase in channel conductance or a
change in voltage dependency—in patients with persistent
AF.
The reduction of Kir6.2 mRNA levels in patients with
persistent AF may be related to depletion of ATP by an
increase in metabolic demand during AF. This depletion of
ATP could promote opening of Kir6.2, leading to enhanced
repolarization (24) and subsequently increased expression of
this channel (25). When activation of Kir6.2 continues, the
myocyte may eventually respond by reducing the gene
expression of this channel. There is still uncertainty whether
atrial ischemia indeed plays a role in triggering electrical
remodeling by AF. First, in a canine model White et al. (26)
demonstrated that induced AF immediately caused an
increase in coronary atrial perfusion and oxygen consump-
tion of atrial myocardium, but without induction of isch-
emia. On the other hand, a progressive increase in metabolic
demand during persistent AF may lead to repeated episodes
of atrial ischemia, contributing to activation of the ATP-
dependent potassium channel. The latter is suggested by
results of Ausma et al. (27), who demonstrated similarities
between cellular structural changes induced by AF and those
seen in hibernating myocardium.
The observed reduction in protein expression of Kv1.5 in
patients with persistent AF and in those with paroxysmal
Figure 1. The top of each panel shows a typical Western blot analysis of
10 mg of protein homogenates of three patients in sinus rhythm (SR), three
patients with persistent (chronic) atrial fibrillation (CAF) and three
patients with paroxysmal AF (PAF). The immunoblots were done for
anti-Kv4.3 (A), anti-Kv1.5 (B), and anti-Kir3.1 (C) with glyceraldehyde-
3-phosphate dehydrogenase (37 kD) as an internal control. All data are
presented as density units/density units. Values are mean 6 SEM.
Figure 2. Correlation between the mean protein expression of Kv4.3
(triangle, r 5 0.67, p . 0.05), Kv1.5 (circle, r 5 0.97, p 5 0.02) and
Kir3.1 (square, r 5 0.56, p . 0.05) in patients with paroxysmal atrial
fibrillation and the duration of sinus rhythm before surgery.
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AF could be due to post-transcriptional changes because, at
the mRNA level, no changes were found between the
groups. The reduction in protein expression is in agreement
with the previous data of Van Wagoner et al. (8) in patients
with persistent AF. However, in a canine model of the
group of Nattel (3), no changes could be found in the
current density of IKur. It should be pointed out that the
molecular species underlying canine IKur, probably Kv3.1, is
to be likely different from that underlying human atrial IKur,
Kv1.5 (28).
No changes in mRNA expression were found for the
HERG gene, the gene encoding the rapid component of the
delayed rectifier. This is in accordance with data of Yue et
al. (3) and suggests that the HERG gene is less involved in
repolarization at the atrial level during AF.
Finally, we observed a positive correlation between the
duration of sinus rhythm before surgery and the protein
levels of Kv1.5 in patients with paroxysmal AF; patients in
AF at the moment of surgery had lower protein levels
compared with patients in sinus rhythm. This finding may
suggest that alterations in protein expression, and possibly
also structural changes, occur early (most paroxysms lasted
,24 h) and could be reversible.
Underlying mechanisms. The observed reduction in gene
expression of three potassium currents clearly cannot explain
the observed shortening of effective refractory period and
action potential duration. One may hypothesize that a
reduction in the potassium channels’ gene expression is an
adaptation mechanism that serves to prolong the initially
reduced atrial effective refractory period and action potential
duration.
The observed discrepancy between alterations in mRNA
and protein expression in patients with paroxysmal AF may
suggest the influence of a different compensatory mecha-
nism. We hypothesize that reduction in protein channels
occurs because of calcium overload (20,29) and structural
changes, including atrophy (27,30), in atrial tissue during
AF by an increased expression of proteolytic enzymes (31).
An increased expression of the proteolytic system is ob-
served in heart tissue during atrophy, calcium overload and
stunning (32–36). Increased protein degradation in muscle
atrophy and calcium overload seemed predominantly in-
duced by activation of a non-lysosomal ATP-dependent
proteolytic process. Medina et al. (31) showed that the
ubiquitin proteasome-dependent pathway, a highly con-
served pathway consisting of ubiquitin, ubiquitin-
conjugating enzymes, deubiquitinases and proteasome, is
activated in atrophying muscles of the heart during starva-
tion. Another common cytosolic proteinase-regulating
pathway in eukaryotes is the calcium-dependent pathway,
which consists of a diverse group of calcium-dependent
cysteine proteinases (calpains in vertebrate tissues) (37). The
increase in cytosolic calcium (29,38) during AF could be an
important activator of this calcium-dependent pathway by
promoting activation of neutral proteases such as calpains,
which once accomplished, leads to proteolysis of numerous
cytoskeletal, membrane-associated and regulatory proteins
(32–35) and, in turn, leads to degeneration of the myocar-
dial cell.
Study limitations. Drugs and differences in underlying
diseases may influence gene expression of ion channels. In
this study, to minimize the influence of particular clinical
parameters on gene expression, we included only patients
with normal LV function, and when possible, drugs were
discontinued before surgery.
Because of the limited amount of tissue available, no
matched controlled analysis could be performed for deter-
mination of protein levels. However, no significant changes
in mRNA levels between the various control groups of
patients in sinus rhythm were observed. Therefore, in our
opinion, a comparison among persistent AF, paroxysmal
AF and sinus rhythm patients seems to be justified.
The paroxysmal AF patients included in this study
represent patients who were difficult to treat and who
underwent predominantly MAZE surgery. Furthermore, it
should be noted that in all groups the number of patients
was small. Therefore, the present data cannot be extrapo-
lated uncritically to all (paroxysmal) AF patients.
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